RPE65- レチノパシーにおけるVoretigene Neparvovecの有効性と安全性:日本における第3相試験の結果
Kaoru Fujinami1,2,3,4,5,6,7, Kunihiko Akiyama2,7, Kazushige Tsunoda2,6,7
1Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, NHO Tokyo Medical Center, Tokyo, Japan.
Ophthalmology science
|September 5, 2025
まとめ
Voretigene neparvovec (VN) 遺伝子治療は,RPE65網膜症の日本人の患者で視力と光感を改善しました. この第3相臨床試験では,この治療は1年以上にわたって好ましい安全性を示した.
科学分野:
- 眼科について
- 遺伝学
- 遺伝子療法
背景:
- RPE65- 網膜症を含む遺伝性網膜縮症は,進行的な視力喪失を引き起こす.
- 遺伝子治療は 盲目の遺伝的原因を 治療する可能性があるのです
- Voretigene neparvovec (VN) は,アデノ関連ウイルスベクターベースの遺伝子療法です.
研究 の 目的:
- 日本人のRPE65網膜症患者におけるvoretigene neparvovec (VN) の有効性と安全性を評価する.
- 視覚機能と光敏感性に対するVNの影響を評価する.
- この患者集団におけるVNの安全性プロファイルを決定する.
主な方法:
- 日本人の患者4人を対象としたオープン・シングル・アーム臨床試験です.
- 参加者は,体外切除術後のVN (1. 5 × 10^11vg) の双方向性注射を受けた.
- 全場光感度値 (FST),視野度 (VF),および1年間にわたって最も改善された視界度 (BCVA) の変化で測定された有効性.
主要な成果:
- 治療開始から1年後の平均FST,VF,BCVAの有意な改善が観察されました.
- 平均 FST は -1.831 log10 ((cd.s/m^2) で改善され,平均 VF は 427.8 度,平均 BCVA は -0.033 LogMAR で改善されました.
- 治療に関連した重大な有害事象はありません.
結論:
- Voretigene neparvovec (VN) 遺伝子治療は,RPE65網膜症の日本人の患者の視覚機能の改善に有望な効果を示しています.
- この治療は1年間の研究期間中に好ましい安全性プロファイルを示した.
- これらの発見は,日本の人口におけるVNの潜在的適用性と利益を支持する.
さらに関連する動画
関連する概念動画
The Retinoblastoma Gene
4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Clinical Trials
7.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
7.5K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Pharmacovigilance
981
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
981
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223


